Results
- Showing results for:
- Reset all filters
Search results
-
Journal articleLythgoe MP, Mullish BH, Frampton AE, et al., 2022,
Polymorphic microbes: a new emerging hallmark of cancer
, Trends in Microbiology, Vol: 30, Pages: 1131-1134, ISSN: 0966-842X -
Journal articlePowles STR, Gallagher KI, Chong LWL, et al., 2022,
Effects of bowel preparation on intestinal bacterial associated urine and faecal metabolites and the associated faecal microbiome
, BMC Gastroenterology, Vol: 22<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Urinary and faecal metabolic profiling have been extensively studied in gastrointestinal diseases as potential diagnostic markers, and to enhance our understanding of the intestinal microbiome in the pathogenesis these conditions. The impact of bowel cleansing on the microbiome has been investigated in several studies, but limited to just one study on the faecal metabolome.</jats:p> </jats:sec><jats:sec> <jats:title>Aim</jats:title> <jats:p>To compare the effects of bowel cleansing on the composition of the faecal microbiome, and the urine and faecal metabolome.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>Urine and faecal samples were obtained from eleven patients undergoing colonoscopy at baseline, and then at day 3 and week 6 after colonoscopy. 16S rRNA gene sequencing was used to analyse changes in the microbiome, and metabonomic analysis was performed using proton nuclear magnetic resonance (<jats:sup>1</jats:sup>H NMR) spectroscopy.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Microbiomic analysis demonstrated a reduction in alpha diversity (Shannon index) between samples taken at baseline and three days following bowel cleansing (<jats:italic>p</jats:italic> = 0.002), and there was no significant difference between samples at baseline and six weeks post colonoscopy. Targeted and non-targeted analysis of urinary and faecal bacterial associated metabolites showed no significant impact following bowel cleansing.</jats:p> </jats:sec><jats:sec>
-
Conference paperRouty B, Lenehan J, Daisley B, et al., 2022,
614 Microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients
, SITC 37th Annual Meeting (SITC 2022) Abstracts, Publisher: BMJ Publishing Group Ltd, Pages: A646-A646 -
Conference paperLythgoe M, Mullish B, Frampton A, et al., 2022,
ORAL ADMINISTRATION OF MRX0518 IN TREATMENTNAIVE CANCER PATIENTS IS ASSOCIATED WITH COMPOSITIONAL TAXONOMIC AND METABOLOMIC CHANGES INDICATIVE OF ANTI-TUMORIGENIC EFFICACY
, Publisher: BMJ PUBLISHING GROUP, Pages: A659-A659 -
Journal articleIaniro G, Mullish BH, Iqbal TH, et al., 2022,
Minimising the risk of monkeypox virus transmission during faecal microbiota transplantation: recommendations from a European expert panel
, The Lancet Gastroenterology & Hepatology, Vol: 7, Pages: 979-980, ISSN: 2468-1253 -
Conference paperMullish BH, Paizs P, Alexander J, et al., 2022,
Intestinal microbiota transplant for recurrent Clostridioides difficile infection restores microbial arylsulfatases and sulfatide degradation: a novel mechanism of efficacy?
, UEG Week 2022, Pages: 823-823 -
Journal articleForlano R, Sivakumar M, Mullish BH, et al., 2022,
Gut microbiota—a future therapeutic target for people with non-alcoholic fatty liver disease: a systematic review
, International Journal of Molecular Sciences, Vol: 23, Pages: 1-13, ISSN: 1422-0067Non-alcoholic fatty liver disease (NAFLD) represents an increasing cause of liver disease, affecting one-third of the population worldwide. Despite many medications being in the pipeline to treat the condition, there is still no pharmaceutical agent licensed to treat the disease. As intestinal bacteria play a crucial role in the pathogenesis and progression of liver damage in patients with NAFLD, it has been suggested that manipulating the microbiome may represent a therapeutical option. In this review, we summarise the latest evidence supporting the manipulation of the intestinal microbiome as a potential therapy for treating liver disease in patients with NAFLD.
-
Journal articleMullish BH, McDonald JAK, Marchesi JR, 2022,
Mechanisms of efficacy of intestinal microbiota transplant: do not forget the metabolites
, The Lancet Gastroenterology & Hepatology, Vol: 7, Pages: 594-594, ISSN: 2468-1253 -
Journal articleGhani R, Mullish BH, Davies FJ, et al., 2022,
How to adapt an intestinal microbiota transplantation programme to reduce the risk of invasive multidrug-resistant infection
, Clinical Microbiology and Infection, Vol: 28, Pages: 502-512, ISSN: 1198-743X -
Journal articleFromentin S, Forslund SK, Chechi K, et al., 2022,
Microbiome and metabolome features of the cardiometabolic disease spectrum
, Nature Medicine, Vol: 28, Pages: 303-+, ISSN: 1078-8956Previous microbiome and metabolome analyses exploring non-communicable diseases have paid scant attention to major confounders of study outcomes, such as common, pre-morbid and co-morbid conditions, or polypharmacy. Here, in the context of ischemic heart disease (IHD), we used a study design that recapitulates disease initiation, escalation and response to treatment over time, mirroring a longitudinal study that would otherwise be difficult to perform given the protracted nature of IHD pathogenesis. We recruited 1,241 middle-aged Europeans, including healthy individuals, individuals with dysmetabolic morbidities (obesity and type 2 diabetes) but lacking overt IHD diagnosis and individuals with IHD at three distinct clinical stages—acute coronary syndrome, chronic IHD and IHD with heart failure—and characterized their phenome, gut metagenome and serum and urine metabolome. We found that about 75% of microbiome and metabolome features that distinguish individuals with IHD from healthy individuals after adjustment for effects of medication and lifestyle are present in individuals exhibiting dysmetabolism, suggesting that major alterations of the gut microbiome and metabolome might begin long before clinical onset of IHD. We further categorized microbiome and metabolome signatures related to prodromal dysmetabolism, specific to IHD in general or to each of its three subtypes or related to escalation or de-escalation of IHD. Discriminant analysis based on specific IHD microbiome and metabolome features could better differentiate individuals with IHD from healthy individuals or metabolically matched individuals as compared to the conventional risk markers, pointing to a pathophysiological relevance of these features.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.
General enquiries
For any enquiries about the Microbiome Network at Imperial, please contact: